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SCREENING FOR PROSTATE CANCER
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Despite recent advances in both the survival and cure rates for many forms of
cancer, unfortunately the same has not been true for prostate cancer. In fact, the age-
adjusted death rate from prostate cancer has not significantly improved since 1949, and
prostate cancer remains the most common cancer in American men, causing the second
highest cancer mortality rate.
Scientific studies have found no consistent correlation of prostate cancer with diet,
venereal disease, sexual habits, smoking, or occupational exposure. However, there does
seem to be correlation with higher serum testosterone levels. It also appears that there
may be a familial tendency for the development of prostate cancer, although no
chromosomal abnormalities have been discovered that can predict whether or not an
individual will develop prostate cancer.
Approximately 100,000 cases of prostate cancer are diagnosed annually, and
28,000 men die each year from this disease. But the good news is that prostate cancer
is a relatively slow growing tumor that also metastasizes (or spreads to other parts of the
body) slowly. It is not uncommon for a man to be diagnosed with prostate cancer, live
for many years, and die of something else completely unrelated to the prostate cancer.
The chance of a man developing clinically evident prostate cancer anytime during
his lifetime is only 6 to 8 percent. Autopsies that were performed on men who died
from causes other than prostate cancer have demonstrated that the chance of their being
microscopic evidence of prostate cancer greatly increases as men get older. About 10
percent of all men in their 50's will have microscopic evidence of prostate cancer. By
the time a man is in his 80's, the chances of his having microscopic evidence of prostate
cancer jumps to 70 percent. But nine out of ten prostate cancers are never detected and
are clinically unimportant because they either do not cause symptoms or do not spread
fast enough.
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To date, there has not been a good screening test that detects the presence of
prostate cancer in men who are without symptoms. In order for a screening test to be
good it should be inexpensive, non-invasive, easy to do, and accurate.
The oldest and most widely used screening test has been the digital rectal
examination. While this test is inexpensive, relatively non-invasive (although some may
argue differently), and easy to do, it is not very accurate. Even given the best situations
and longest fingers, a physician can only feel about 9 percent of the entire surface of the
prostate gland.
In April 1991, the New England Journal of Medicine published an article that
suggested using a blood test that measures the level of prostate-specific antigen (PSA) as
a screening test for prostate cancer. PSA is a protein that is only made in certain
prostate cells called epithelial cells. The level of this protein is elevated in between 25
and 92 percent of patients with prostate cancer, but it is also elevated in 30 to 50 percent
of patients with an enlarged prostate gland (a condition called benign prostate
hypertrophy which affects practically every man over the age of 30 to varying degrees),
and in patients with an infection of the prostate gland.
The PSA test is not a new test, but has been available for several years. It has
been an extremely useful test to help monitor the progression of prostate cancer in a
patient who is known to have prostate cancer. But its usefulness as a screening test is
debatable. Reviewing the four criteria of a good screening test, the PSA test is not
particularly inexpensive. The average price of the PSA test is about $100.00 (prices may
vary depending on which laboratory does the test). The test is fairly non-invasive (only
requiring a needlestick to obtain the blood), and is easy to do, although you must send
the blood to a specialized laboratory which may not always be accessible. However, the
biggest controversy over the PSA test is with its accuracy.
Physicians and epidemiologists measure a test's accuracy by virtue of its
"sensitivity" and "specificity." Simply defined, "sensitivity" is the measurement of the
ability of a test to be positive when the disease is actually present, whereas "specificity"
is a measurement of the ability of a test to be negative when the disease is not present.
Because of the relatively high rate of both false positive and false negative tests, the PSA
test is neither very sensitive or specific. The published sensitivity rates for the PSA test
are around 80 percent, with specificity rates between 38 and 56 percent. In other words,
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when an individual has prostate cancer the PSA will be positive only 80 percent of the
time, thereby missing 20 percent of the cases of prostate cancer (a false negative test).
Similarly, if an individual does not have prostate cancer, then the PSA will be negative
only 38 to 56 percent of the time, thereby yielding a false positive test 44 to 62 percent
of the time. Given the PSA test's high false positive and false negative rates, the
accuracy of the test in diagnosing either the presence or absence of prostate cancer in
asymptomatic men is greatly diminished.
Because of the PSA test's inaccuracy and relatively high cost, it does not fulfill
the criteria of a good screening test. However, the PSA test can be very useful in many
circumstances. If a prostate nodule is detected on rectal exam, the PSA test can help
determine whether or not the nodule is malignant. As previously stated, the PSA test is
excellent at following the course of a patient who is known to have prostate cancer. And
the PSA test is excellent at diagnosing prostate cancer that has metastasized (or spread)
beyond the prostate gland when the primary tumor is so small that it cannot be felt. I
also recommend the PSA test for men with certain risk factors for prostate cancer,
specifically if they are over the age of 50, have a strong family history of prostate cancer
(especially if the family members with prostate cancer were diagnosed at a relatively
young age), or if a patient has symptoms of urinary obstruction.
Currently, the Occupational Medicine Services (OMS) at Lewis encourages all
male employees over the age of 40 to get at least an annual rectal exam, which is
available to all government employees during their annual health screening physical
offered through OMS. The American Cancer Society and the National Cancer Institute
recommend the annual rectal exam for men over the age of 40, but the U.S. Preventive
Services Task Force states there is insufficient evidence to recommend either for or
against the annual rectal exam. Currently, none of these groups advocate the PSA test
as a screening tool for prostate cancer in men without symptoms. However, if you feel
that you should have a PSA test, please talk with your personal physician for further
information.
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